Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Clinical trial NCT04849910 · TERMINATED

Trial details

NCT number: NCT04849910
Sponsor: Vor Biopharma
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute Myelodysplastic Syndromes

Start date: 2021-12-16
Primary completion: 2025-05-28
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.